EUCTR2017-000589-31-IT进行中（未招募）1 期
multi stage phase II trial of Nivolumab (an anti –PD-1) in patients with platinum resistant Mismatch Repair deficient germinal cells tumours - NEMESIS- Nivolumab in pre-treated advanced germ cells tumours patients with Mismatch repair deficien
SOCIETà CAMPANA DI IMMUNOTERAPIA ONCOLOGICA0 个研究点目标入组 38 人开始时间: 2021年6月8日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 38
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1)Signed and dated IRB/IEC-approved Informed Consent;
- •2)Male patients> 18 years;
- •3)Life expectancy > 3 months;
- •4)Performance status (ECOG) = 2;
- •5)Histological or clinical diagnosis of GCTs;
- •6)Availability of archival tissue (paraffine block or at least 10 unstained slides) to evaluate the PD-L1 status, which is positive (expression = 1 percent of tumour cells) or negative;
- •7)Microsatellite instability (MSI) and/or DNA repair defects including mismatch-repair gene deficiency (MMR-).
- •8)Either gonadal or extragonadal tumour primary;
- •9)Failure of = 2 prior chemotherapy regimens for metastatic GCT disease (1-2 cycles PEB or 1 cycle carboplatinum AUC7 given in the adjuvant setting for clinical stage I disease will not be counted as prior lines);¿
- •10)Brain metastases: patients who present with brain metastases as the sole site of disease relapse/progression are not allowed to enter the study. Otherwise, patients with massive systemic spread with brain metastases will be allowed to enrol into the study, provided that they will not undergo concomitant brain radiation, brain surgery or they are judged to be at high-risk of bleeding (high-volume metastases with haemorrhagic spots resulting at either CT or ¿MRI scan of the brain);
- •11)Patients must have recovered from toxicity related to prior therapy to at least grade 1 (defined by v.CTCAE 4.0);
- •12)Patients must not have had major surgery, radiation therapy, chemotherapy, biologic therapy (including any investigational agents), or hormonal therapy (other than replacement), within 3 weeks prior to entering the study;
- •13)Patients must have adequate organ and marrow function (as defined below). Patients must have returned to baseline or grade 1 from any acute toxicity related to prior therapy. Laboratory test must be performed within 3 days before date of treatment
- •1.Absolute neutrophil count = 1,500/mm;
- •2.Hemoglobin = 9 g/dL;
- •3.Platelets = 100,000/mm;
- •4.Total bilirubin = 1.5 x institutional upper limit of normal (ULN), except for patients affected by Gilbert’s syndrome;
- •5.AST(SGOT)/ALT(SGPT) = 3 x institutional ULN (5x if LFT elevations due to liver metastases);
- •14)Male who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception starting with the first dose of study therapy through 7 months after the last dose of study therapy.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 19
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 19
排除标准
- •1)Patients with symptomatic brain metastases should be excluded from this clinical trial because of their poor prognosis and because of the steroids administration. However, patients who have had treatment for their brain metastases and whose brain metastatic disease status has remained stable for at least 3 months without steroids may be enrolled at the discretion of the investigator;
- •2)Patients with a diagnosis of immunodeficiency or is receiving steroid therapy and/or immunosuppressive therapy within 7 days before the treatment starting;
- •3)Patients with a diagnosis of active autoimmune disease requiring systemic treatment within the past 90 days, or a documented history of clinically severe autoimmune disease, that requires systemic steroids and/or immunosuppressive agents. Patients with vitiligo or resolved asthma/atopy or stable hypothyroidism, will not be excluded from the trial;
- •4)Major surgery, other than diagnostic surgery, within 4 weeks prior to treatment;
- •5)Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy;
- •6)Previous (within the last 5 years) or current malignancies at other sites, except for basal cell or squamous cell skin cancer that have undergone potentially curative treatment;
- •7)Current enrolment in or participation in another therapeutic clinical trial within 4 weeks before the first dose of treatment;
- •8)Patients with uncontrolled or significant cardiovascular disease within 12 months, unstable angina within 6 months, NYHA Class III, poorly controlled hypertension, ongoing symptomatic cardiac dysrhythmias and uncontrolled atrial fibrillation;
- •9)Known HIV infection;
- •10)Patients with a diagnosis of interstitial lung disease or non-infectious pneumonitis;
- •11)Patient with a diagnosis of active hepatitis B (HBsAg reactive) or C (HCV-RNA qualitative is detected);
- •12)Patients who received a live vaccine one month before the treatment starting;
- •13)Patients who received treatment with mAb within one month before the first dose of trial treatment;
- •14)Patients who have had radiotherapy or chemotherapy within 14 days of the first dose of trial treatment.
研究者
相似试验
进行中（未招募）
1 期
A Study of Nivolumab and Nivolumab Combinations in Recurrent and Metastatic Colon CancerEUCTR2013-003939-30-BEBristol-Myers Squibb International Corporation375
进行中（未招募）
1 期
A Study of Nivolumab and Nivolumab Combinations in Recurrent and Metastatic Colon CancerMSI Positive Colorectal CancerMSI Negative Colorectal CancerMedDRA version: 21.0Level: PTClassification code 10061451Term: Colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-003939-30-IEBristol-Myers Squibb International Corporation375
进行中（未招募）
不适用
A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon CancerMSI Positive Colorectal CancerMSI Negative Colorectal CancerMedDRA version: 16.1Level: PTClassification code 10061451Term: Colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-003939-30-ITBristol-Myers Squibb International Corporation115
进行中（未招募）
不适用
A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon CancerMSI Positive Colorectal CancerMSI Negative Colorectal CancerMedDRA version: 16.1Level: PTClassification code 10061451Term: Colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-003939-30-ESBristol-Myers Squibb International Corporation115
招募中
2 期
Phase Ib /II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination with Ipilimumab in Pediatric Subjects with High Grade Primary CNS MalignanciesNL-OMON48940Bristol-Myers Squibb6